Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Neurodegenerative Disease

PUBLISHER: Grand View Research | PRODUCT CODE: 1405775

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1405775

Epilepsy Drugs Market Size, Share & Trends Analysis Report By Product (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), By Region, And Segment Forecasts, 2023 - 2030

PUBLISHED:
PAGES: 91 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Epilepsy Drugs Market Growth & Trends:

The global epilepsy drugs market size is expected to reach USD 15.35 billion by 2030, registering a CAGR of 5.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Epilepsy Drugs Market Report Highlights:

  • Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel (Fycompa).
  • The third generation anti-epileptics segment accounted for the largest revenue share of around 39.3% in 2022. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
  • North America dominated the market with the largest revenue share of around 45% in 2022. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.
  • Asia Pacific is estimated to expand at the highest CAGR of 6.3% over the forecast period. The presence of favorable government initiatives such as the Intersectoral Global Action Plan on Epilepsy, Global Campaign Against Epilepsy, and others, as well as the launch of new-generation anti-epileptic drugs are the drivers expected to propel the growth of this market in the region.
Show more
Product Code: 978-1-68038-958-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Penetration & Growth Prospect Mapping
  • 3.5. Global Epilepsy Drug Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape

Chapter 4. Epilepsy Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Epilepsy Drug Market: Key Takeaways
  • 4.2. Epilepsy Drug Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 4.3. First Generation Anti-epileptics
    • 4.3.1. First generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Second Generation Anti-epileptics
    • 4.4.1. Second generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Third Generation Anti-epileptics
    • 4.5.1. Third generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Epilepsy Drugs Market: Regional Estimates & Trend Analysis, by Drug

  • 5.1. Regional Outlook
  • 5.2. Epilepsy Drug Market by Region: Key Marketplace Takeaways
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Sweden
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Norway
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. Saudi Arabia
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. South Africa
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. UCB S.A., Belgium
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Product Benchmarking
      • 6.2.1.4. Strategic Initiatives
    • 6.2.2. Sanofi
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Performance
      • 6.2.2.3. Product Benchmarking
      • 6.2.2.4. Strategic Initiatives
    • 6.2.3. Pfizer, Inc.
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Financial Performance
      • 6.2.3.3. Product Benchmarking
      • 6.2.3.4. Strategic Initiatives
    • 6.2.4. Otsuka America Pharmaceutical, Inc.
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Financial Performance
      • 6.2.4.3. Product Benchmarking
      • 6.2.4.4. Strategic Initiatives
    • 6.2.5. Eisai Co., Ltd.
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Performance
      • 6.2.5.3. Product Benchmarking
      • 6.2.5.4. Strategic Initiatives
    • 6.2.6. Novartis AG
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Financial Performance
      • 6.2.6.3. Product Benchmarking
      • 6.2.6.4. Strategic Initiatives
    • 6.2.7. Abbott Laboratories, Inc.
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Financial Performance
      • 6.2.7.3. Product Benchmarking
      • 6.2.7.4. Strategic Initiatives
    • 6.2.8. Sanofi Aventis S.A.
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Financial Performance
      • 6.2.8.3. Product Benchmarking
      • 6.2.8.4. Strategic Initiatives
    • 6.2.9. GlaxoSmithKline plc
      • 6.2.9.1. Company Overview
      • 6.2.9.2. Financial Performance
      • 6.2.9.3. Product Benchmarking
      • 6.2.9.4. Strategic Initiatives
    • 6.2.10. Sunovion Pharmaceuticals, Inc.
      • 6.2.10.1. Company Overview
      • 6.2.10.2. Financial Performance
      • 6.2.10.3. Product Benchmarking
      • 6.2.10.4. Strategic Initiatives
    • 6.2.11. Jazz Pharmaceuticals plc
      • 6.2.11.1. Company Overview
      • 6.2.11.2. Financial Performance
      • 6.2.11.3. Product Benchmarking
      • 6.2.11.4. Strategic Initiatives
    • 6.2.12. Neurelis, Inc.
      • 6.2.12.1. Company Overview
      • 6.2.12.2. Financial Performance
      • 6.2.12.3. Product Benchmarking
      • 6.2.12.4. Strategic Initiatives
Show more
Product Code: 978-1-68038-958-6

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 4 U.S. epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 5 Canada epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 6 Europe epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 7 Europe epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 8 Germany epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 9 UK epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 10 France epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 11 Italy epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 12 Spain epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 13 Sweden epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 Norway epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 15 Denmark epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 18 China epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 19 Japan epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 20 India epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 21 Thailand epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 22 Australia epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 23 South Korea epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 24 Latin America epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 25 Latin America epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 26 Brazil epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 27 Mexico epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 28 Argentina epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 31 South Africa epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 UAE epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 34 Kuwait epilepsy drugs market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Epilepsy drug market: Market outlook
  • Fig. 9 Epilepsy drug market: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Epilepsy drug market driver impact
  • Fig. 15 Epilepsy drug market restraint impact
  • Fig. 16 Epilepsy drug market strategic initiatives analysis
  • Fig. 17 Epilepsy drug market: Product movement analysis
  • Fig. 18 Epilepsy drug market: Product outlook and key takeaways
  • Fig. 19 First generation anti-epileptics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Second generation anti-epileptics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Third generation anti-epileptics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Global epilepsy drug market: Regional movement analysis
  • Fig. 23 Global epilepsy drug market: Regional outlook and key takeaways
  • Fig. 24 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!